Task Order 4: Nonclinical Toxicology Study of an Investigational Agent in Development for Anticancer Therapy

任务顺序 4：抗癌治疗研究药物的非临床毒理学研究

• 批准号: 8939015
• 负责人: TOUFAN PARMAN
• 金额: $ 13.32万
• 依托单位: SRI INTERNATIONAL
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-07-01 至 2016-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8939015
• 关键词: Award; Contracts; Development; Investigation; Malignant Neoplasms; Organ; Pharmaceutical Preparations; Process; Testing; Toxic effect; Toxicology; anti-cancer therapeutic; anticancer activity; cancer therapy; research clinical testing

The test agent is being considered for development as an anticancer therapeutic. The objective of this task was to characterize the target organ toxicities of an investigative agent that might move forward to clinical testing for anticancer activity. The information obtained from this investigation was used to identify drugs with the potential to treat cancer.

测试剂被视为开发为抗癌治疗。 该任务的目的是表征研究剂的靶器官毒性，该剂可能会继续进行抗癌活性的临床测试。 从本研究中获得的信息用于识别具有治疗癌症潜力的药物。